Plant Compounds Show Early Promise for Macular Decline

In a small trial, adults with early AMD who took a resveratrol, quercetin, and curcumin combination saw drusen shrink over two years.

Updated on Nov. 3, 2026 in Health

Isometric editorial illustration of three distinct geometric plant-compound blocks in mustard, oxblood, and teal arranged on a pale plinth, representing a supplement study for early macular degeneration.
A University of Illinois Chicago trial found a resveratrol, quercetin, and curcumin combination shrank drusen deposits in early macular degeneration over two years, though researchers call the results preliminary. AI Illustration. Upload story photo >

A University of Illinois College of Medicine Chicago trial found that a combination of resveratrol, quercetin, and curcumin reduced drusen volume in people with early and intermediate age-related macular degeneration (AMD) over two years, though the results are preliminary. The findings concern adults with early and intermediate AMD, a condition that is most common in people over 50.

Why it matters

AMD is a leading cause of vision loss in older adults, and there is currently no widely available approach that targets the inflammatory and oxidative processes behind the disease at this stage. The study tests whether a supplement-based strategy aimed at those shared pathways could slow early changes in the eye as the population ages.

This phase 2a randomized trial enrolled 38 people with early and intermediate AMD and gave them either oral RQC or curcumin for two years. Drusen volume fell 13.4% in the RQC group but rose 6.9% in the curcumin group, though differences in visual acuity were not statistically significant and the findings remain preliminary.

The players

University of Illinois College of Medicine Chicago

The medical school that conducted the phase 2a trial, with research programs in eye and vision science.

Translational Vision Science and Technology

The peer-reviewed journal in which the trial results were published, focused on vision research and clinical eye care.

The details

The RQC formulation combined 800 mg per day of curcuminoids with 200 mg per day each of trans-resveratrol and quercetin, and was designed to target inflammatory and oxidative stress pathways involved in age-related degenerative diseases. Curcumin, resveratrol, and quercetin act at complementary points within those pathways. Researchers used drusen volume, the fatty protein deposits that build up under the retina, to track disease progression.

Timeline

  1. Participants took the oral supplements for two years during the trial.

  2. The study was published in Translational Vision Science and Technology in 2026.

Health Landscape

Antioxidant vitamin and zinc formulations from the National Eye Institute's AREDS trials remain the best-established nutritional approach for intermediate AMD. This small phase 2a study explores whether plant-derived compounds acting on shared inflammatory pathways could add to that evidence base.

If you are over 50 or have a family history of AMD, this study is a reminder to ask your eye doctor about regular dilated eye exams and changes in your central vision. Any decision about adding supplements such as curcumin, resveratrol, or quercetin is worth discussing with your physician before you start.

The takeaway

The trial is small and preliminary, so it does not establish that these supplements protect vision. Keep up regular eye exams after age 50, and bring any interest in supplements to your doctor.

Further reading

For more on how plant compounds are being studied for health, see the Nutrition section.

Source note: This article includes information reported by NutraIngredients.